The government office that oversees Medicare and Medicaid has reimbursed prescription drugs at market costs, instead of at optional lower rates that could potentially save taxpayers millions of dollars a year, a government investigation has found.
The Centers for Medicare and Medicaid Services (CMS) reimburses prescription drug purchases by beneficiaries through Medicare Part B. The cost is supposed to be no more than five percent above what it takes to manufacture the drugs.
Instead of using optional lower prices, federal agency is reimbursing drugs at expensive market prices
